公开(公告)号：US10562956B2

公开(公告)日：2020-02-18

申请号：US15331942

申请日：2016-10-24

Applicant: Mallinckrodt Pharma IP Trading D.A.C., an Irish Designated Activity Company

Inventor： Abraham Bout ,  Joseph Grimbergen ,  Jacob Koopman

IPC: C07K14/75 ,  C07H21/04 ,  C12N15/09

Abstract: The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.

公开(公告)号：US10004787B2

公开(公告)日：2018-06-26

申请号：US15614157

申请日：2017-06-05

Applicant: Mallinckrodt Pharma IP Trading D.A.C.

Inventor： Joseph Grimbergen ,  Jacob Koopman ,  Abraham Bout

IPC: A61K38/00 ,  A61K38/36 ,  C07K14/75 ,  C12P21/00

CPC classification number: A61K38/363 ,  A61K38/4833 ,  C07K14/75 ,  C12P21/005 ,  A61K2300/00

Abstract: The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen.

公开(公告)号：US09694054B2

公开(公告)日：2017-07-04

申请号：US14877354

申请日：2015-10-07

Applicant: Mallinckrodt Pharma IP Trading D.A.C.

Inventor： Joseph Grimbergen ,  Jacob Koopman ,  Abraham Bout

IPC: C12Q1/56 ,  C12P21/04 ,  A61K38/00 ,  C07K14/75 ,  A61K38/36 ,  C12P21/00

CPC classification number: A61K38/363 ,  A61K38/4833 ,  C07K14/75 ,  C12P21/005 ,  A61K2300/00

Abstract: The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen.

公开(公告)号：US20170266262A1

公开(公告)日：2017-09-21

申请号：US15614157

申请日：2017-06-05

Applicant: Mallinckrodt Pharma IP Trading D.A.C.

Inventor： Joseph Grimbergen ,  Jacob Koopman ,  Abraham Bout

IPC: A61K38/36 ,  C12P21/00

CPC classification number: A61K38/363 ,  A61K38/4833 ,  C07K14/75 ,  C12P21/005 ,  A61K2300/00

Abstract: The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen.

公开(公告)号：US20170037108A1

公开(公告)日：2017-02-09

申请号：US15331942

申请日：2016-10-24

Applicant: Mallinckrodt Pharma IP Trading D.A.C., an Irish Designated Activity Company

Inventor： Abraham Bout ,  Joseph Grimbergen ,  Jacob Koopman

IPC: C07K14/75

Abstract: The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.

Abstract translation: 本发明涉及编码纤维蛋白原α，β或γ链的核苷酸序列。 优化序列在真核细胞培养系统中表达。 这种优化的核苷酸序列允许在真核细胞培养系统中以完整形式有效地表达重组纤维蛋白原及其变体。